Latigo Biotherapeutics files initial beneficial ownership statement for Sanofi

Sanofi filed a Form 3 with the SEC, disclosing an initial beneficial ownership stake of 10% in Latigo Biotherapeutics as of August 6, 2026. The filing details indirect ownership of 494,800 shares of Series B Preferred Stock and 177,978 shares underlying a Convertible Promissory Note.

Sanofi filed a Form 3 disclosing 10% ownership in Latigo Biotherapeutics as of Aug. 6, 2026. * Indirect beneficial ownership of 494,800 shares underlying Series B Preferred Stock. * Indirect beneficial ownership of 177,978 shares underlying a Convertible Promissory Note. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-345811), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

SNY